- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00476177
Donor Dendritic Cells And Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogeneic Transplant
March 28, 2012 updated by: Edwin P. Alyea, MD, Dana-Farber Cancer Institute
Infusion of Donor Dendritic Cells and Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogenic Transplant
The purpose of this study is to test the safety of adding donor dendritic cells to donor lymphocyte infusions, and to determine the type and severity of any side effects associated with this addition.
Previously patients with hematologic malignancies who relapsed after transplant have been given infusions of donor white blood cells (donor lymphocyte infusion, DLI) as a way to boost their immune function and fight disease.
Although DLI has led to cancer regression in some patients, the overall response rate using DLI alone is low, and unfortunately, rarely lasting.
Researchers have discovered a new subset of blood cells, called dendritic cells (DC), which are crucial partners to lymphocytes in generating an immune response.
We believe that the infusion of DC together with DLI may improve the ability of the donor lymphocytes to recognize and kill cancer cells.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
- Since we are looking for the highest dose of donor dendritic cells that can be administered safely with DLI patients after allogeneic stem cell transplant, not everyone who participates in this study will be receiving the same number of dendritic cells.
- The study procedure can be divided into 3 phases: 1) Pre-infusion evaluation, 2) Cell collections and infusions, 3) Follow-up after infusions.
- Pre-infusion evaluation: Routine blood tests will be performed on both the participant and donor. The participant will undergo a bone marrow aspirate and biopsy if this has not been recently performed. During this time, additional standard blood tests and/or radiology tests may be done to fully determine the extent of the cancer.
- Cell Collections: About 2-3 weeks before the infusion date, the donor will undergo one or two white blood cell collection procedures called leukopheresis. The cells collected from the first leukopheresis will be sent to the laboratory where a portion will be used to cultivate dendritic cells, and the remaining lymphocytes will be set aside for the DLI. If the number of cells collected at the first leukopheresis is insufficient, the donor will undergo a second leukopheresis procedure 7-10 days later.
- Infusions: We plan to administer the dendritic cells and donor lymphocytes separately in the outpatient clinic. The dendritic cells will be given first, followed by the DLI one to two days later.
- Follow-up after infusions: After completion of both the donor DC and DLI, participants will be followed closely for the development of side effects and response. They will be evaluated at least once a week, and routine blood tests and physical examination to assess for graft vs. host disease (GvHD) or other side effects will be performed. Additional blood tests will be done after 3, 6, and 10 weeks. At 10 weeks after the lymphocyte infusion, bone marrow aspirate and biopsy will be performed to assess the disease as well as the percentage of bone marrow cells that are derived from the donor. Additional restaging studies will also be performed at 10 weeks.
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, United States, 02115
- Beth Israel Deaconess Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with hematologic malignancies who have relapsed after related or unrelated donor hematopoietic stem cell transplantation (e.g. CML, AML, ALL, MDS, NHL, HD, CLL, MM)
- At least two months following hematopoietic stem cell transplantation
- Patients off any systemic immunosuppressive medication for treatment or prevention of GVHD for minimum of 2 weeks prior to initiation of therapy
- 18 years of age or older
- ECOG performance status 0-2
- Donor medically fit to undergo leukapheresis procedure
Exclusion Criteria:
- Relapsed CML in chronic phase
- Prior donor lymphocyte infusion or other immunotherapy treatment within 8 weeks of enrollment
- Clinically significant and active autoimmune disease in donor or patient
- Evidence of active grade II-IV acute GVHD or active extensive chronic GVHD
- Uncontrolled infection
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the maximum tolerated dose of allogeneic DC in combination with DLI in patents with a relapsed hematologic malignancy following allogeneic hematopoietic stem cell transplantation.
Time Frame: 4 years
|
4 years
|
Secondary Outcome Measures
Outcome Measure |
---|
To assess clinical response after infusions of donor derived DC and donor lymphocytes
|
To assess the immunologic impact of infusions of donor derived DC and donor lymphocytes.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Edwin Alyea, MD, Dana-Farber Cancer Institute
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2003
Primary Completion (Actual)
August 1, 2007
Study Completion (Actual)
July 1, 2009
Study Registration Dates
First Submitted
May 18, 2007
First Submitted That Met QC Criteria
May 18, 2007
First Posted (Estimate)
May 21, 2007
Study Record Updates
Last Update Posted (Estimate)
March 29, 2012
Last Update Submitted That Met QC Criteria
March 28, 2012
Last Verified
March 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 02-003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematologic Malignancy
-
St. Jude Children's Research HospitalRecruitingRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyUnited States
-
CRISPR Therapeutics AGEnrolling by invitationHematologic Malignancy | Solid MalignancyUnited States
-
Epizyme, Inc.WithdrawnRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyUnited States
-
Scripps Translational Science InstituteCompleted
-
Millennium Pharmaceuticals, Inc.Completed
-
Guardant Health, Inc.CompletedNon-Hematologic MalignancyUnited States
-
CCTU- Cancer ThemeRecruitingCancer | Non-Hematologic MalignancyUnited Kingdom
-
Century Therapeutics, Inc.RecruitingHematological Malignancy | Solid Tumor MalignancyUnited States
-
Princess Maxima Center for Pediatric OncologyRecruitingRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyNetherlands
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingHematologic MalignancyChina
Clinical Trials on Infusion of donor dendritic cells
-
Martín, José Luis Díez, M.D.Completed
-
Assistance Publique - Hôpitaux de ParisPierre and Marie Curie University; Université Paris XIICompletedHematologic Neoplasms | RelapseFrance
-
Angus W. Thomson PhD DScUniversity of PittsburghActive, not recruiting
-
Mitchell Horwitz, MDCompletedHematological MalignanciesUnited States
-
Stanford UniversityNorthwestern University; California Institute for Regenerative Medicine (CIRM)RecruitingLiving Donor Kidney TransplantationUnited States
-
Imperial College LondonWithdrawnAllogeneic Stem Cell Transplant | Haematological Malignancies | CD56+CD3- NK CellsUnited Kingdom
-
Pawel KalinskiNational Cancer Institute (NCI)CompletedMelanoma (Skin)United States
-
H. Lee Moffitt Cancer Center and Research InstituteThe Shulas' FoundationRecruitingTriple Negative Breast Cancer | HER2-negative Breast CancerUnited States
-
Jonsson Comprehensive Cancer CenterKite, A Gilead CompanyCompletedClear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell CancerUnited States
-
Fundació Sant Joan de DéuInstitut d'Investigacions Biomèdiques August Pi i SunyerUnknownDiffuse Intrinsic Pontine GliomaSpain